261 related articles for article (PubMed ID: 25260362)
1. Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin.
Bogdanffy MS; Stachlewitz RF; van Tongeren S; Knight B; Sharp DE; Ku W; Hart SE; Blanchard K
Int J Toxicol; 2014; 33(6):436-49. PubMed ID: 25260362
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of Renal Injury and Gene Expression Changes in the Male CD-1 Mouse Associated with Exposure to Empagliflozin.
Knight B; Yuan J; Koegler S; Pande P; Hall J; Hill JD; Hart SE; Phillips JA; Ku WW
Toxicol Pathol; 2018 Aug; 46(6):671-682. PubMed ID: 29945496
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Tirmenstein M; Dorr TE; Janovitz EB; Hagan D; Abell LM; Onorato JM; Whaley JM; Graziano MJ; Reilly TP
Int J Toxicol; 2013; 32(5):336-50. PubMed ID: 24097127
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
6. A Predominant Oxidative Renal Metabolite of Empagliflozin in Male Mice Is Cytotoxic in Mouse Renal Tubular Cells but not Genotoxic.
Smith JD; Huang Z; Escobar PA; Foppiano P; Maw H; Loging W; Yu H; Phillips JA; Taub M; Ku WW
Int J Toxicol; 2017; 36(6):440-448. PubMed ID: 29130831
[TBL] [Abstract][Full Text] [Related]
7. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
9. NTP technical report on the toxicology and carcinogenesis studies of beta-myrcene (CAS No. 123-35-3) in F344/N rats and B6C3F1 mice (Gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2010 Dec; (557):1-163. PubMed ID: 21415873
[TBL] [Abstract][Full Text] [Related]
10. Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin.
Phillips JA; Taub ME; Bogdanffy MS; Yuan J; Knight B; Smith JD; Ku WW
J Appl Toxicol; 2022 Oct; 42(10):1570-1584. PubMed ID: 35393688
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 Apr; 450():1-321. PubMed ID: 12594525
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
Macha S; Rose P; Mattheus M; Cinca R; Pinnetti S; Broedl UC; Woerle HJ
Diabetes Obes Metab; 2014 Feb; 16(2):118-23. PubMed ID: 23859534
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
15. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Nitrofurantoin (CAS No. 67-20-9) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 Sep; 341():1-218. PubMed ID: 12724784
[TBL] [Abstract][Full Text] [Related]
19. Toxicology and Carcinogenesis Studies of C.I. Pigment Red 3 (CAS No. 2425-85-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1992 Mar; 407():1-289. PubMed ID: 12621523
[TBL] [Abstract][Full Text] [Related]
20. Toxicology and carcinogenesis studies of benzophenone (CAS No. 119-61-9) in F344/N rats and B6C3F1 mice (feed studies).
Natl Toxicol Program Tech Rep Ser; 2006 Feb; (533):1-264. PubMed ID: 16741556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]